Učitavanje...
Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma
Survivin is an anti-apoptotic protein that is highly expressed in many cancers, including malignant gliomas. Preclinical studies established that the conjugated survivin peptide mimic SurVaxM (SVN53-67/M57-KLH) could stimulate an anti-tumor immune response against murine glioma in vivo, as well as h...
Spremljeno u:
| Izdano u: | Cancer Immunol Immunother |
|---|---|
| Glavni autori: | , , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Springer Berlin Heidelberg
2016
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5069322/ https://ncbi.nlm.nih.gov/pubmed/27576783 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-016-1890-x |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|